Physician profile
Krissy Choi
NPI 1871864371
$9,635.38
in general payments reported to CMS, 2019-2025
36 companies · $1,909 in 2025
The $1,909 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,368 · 2020: $853 · 2021: $898 · 2022: $1,285 · 2023: $1,620 · 2024: $1,704 · 2025: $1,909.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,094 · Education: $138.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,094.05 |
| Education | $138.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,900.93 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Amgen INC. | $1,573.86 | 2019-2025 | Enbrel, Tavneos, Otezla |
| Novartis Pharmaceuticals Corporation | $1,371.41 | 2019-2025 | |
| Pfizer INC. | $994.01 | 2019-2025 | |
| Janssen Biotech, INC. | $715.61 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Ucb, INC. | $424.01 | 2019-2025 | Bimzelx, Cimzia |
| Glaxosmithkline, LLC. | $316.69 | 2019-2025 | Benlysta |
| Genzyme Corporation | $315.43 | 2019-2025 | |
| Lilly USA, LLC | $257.98 | 2019-2023 | Taltz |
| Astrazeneca Pharmaceuticals LP | $254.96 | 2022-2025 | Saphnelo |
| E.R. Squibb & Sons, L.L.C. | $248.87 | 2019-2025 | Orencia |
| Aurinia Pharma U.S., INC. | $201.53 | 2022-2025 | Lupkynis |
| Genentech USA, INC. | $132.17 | 2019-2024 | Actemra |
| Horizon Therapeutics Plc | $88.03 | 2020-2023 | Krystexxa |
| Organon LLC | $85.53 | 2023-2025 | Hadlima, Renflexis |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Therapeutics, INC. | $75.66 | 2019-2020 | |
| Sobi, INC | $73.67 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.30 | 2020-2025 | Jascayd, Cyltezo |
| Ani Pharmaceuticals, INC. | $71.21 | 2024-2025 | Purified Cortrophin Gel |
| Mallinckrodt Hospital Products INC. | $56.34 | 2023-2025 | Acthar |
| Ferring Pharmaceuticals INC. | $49.46 | 2023-2025 | Euflexxa |
| Celgene Corporation | $43.98 | 2019 | |
| Bioventus LLC | $42.61 | 2022-2023 | Durolane |
| Radius Health, INC. | $37.20 | 2019-2025 | Tymlos |
| Sanofi-Aventis U.S. LLC | $32.68 | 2020-2023 | |
| Kiniksa Pharmaceuticals International, Plc | $28.39 | 2024 | Arcalyst |
| Hikma Pharmaceuticals USA | $26.83 | 2019-2020 | |
| Ultragenyx Pharmaceutical INC. | $20.36 | 2023 | Crysvita |
| Alvogen INC | $20.00 | 2025 | Teriparatide |
| Scpharmaceuticals INC. | $19.78 | 2025 | |
| Sandoz INC. | $16.12 | 2024 | Hyrimoz |
| Kiniksa Pharmaceuticals, LTD. | $14.90 | 2021 | |
| Janssen Pharmaceuticals, INC | $14.80 | 2024 | Xarelto |
| Sebela Pharmaceuticals INC. | $13.08 | 2019 | |
| Vertical Pharmaceuticals, LLC | $12.95 | 2019 | |
| Medexus Pharma, INC. | $12.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Krissy Choi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.